Beverly Hills Cancer Center Clinical Research Advisors LLC, Beverly Hills
UC Irvine Health Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Valkyrie Clinical Trials, Los Angeles
agus 1 a bharrachd

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07518186

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Research Site, Duarte

A’ fastadhÌre 1

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07073547

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

Berenson Cancer Center, Los Angeles

A’ fastadhÌre 4

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07609940

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

University of California San Francisco, San Francisco

A’ fastadhÌre 2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06500884

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

City of Hope - Duarte, Duarte
City of Hope - Lennar, Irvine

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07336472

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

UCSF Fresno, Clovis
City of Hope Duarte, Duarte
City of Hope Orange County Lennar Foundation Cancer Center, Irvine
agus 2 a bharrachd

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT05552222

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

UCSF, San Francisco

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07116616

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Sutter Auburn, Auburn
Sutter Alta Bates, Berkeley
The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles
agus 19 a bharrachd

A’ fastadhÌre 2

Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT02693535

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Cedars-Sinai Medical Center /ID# 278238, Los Angeles

A’ fastadhÌre 2/3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07095452

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

UC Irvine, Orange

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Sult 2026 · NCT07648264

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

University of California, San Francisco, San Francisco

A’ fastadhÌre 1

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Sult 2026 · NCT05892393

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

UCLA Hematology/Oncology - Santa Monica, Los Angeles
University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Sult 2026 · NCT06615479

Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities

University of California Davis Comprehensive Cancer Center, Sacramento

A’ fastadhSgrùdadh amharc

Aoisean 21 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT04314752

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

UCLA Hematology/Oncology - Westwood (Building 200 Suite 214), Los Angeles
UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco

A’ fastadhÌre 2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT06297226

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

University of Southern California /ID# 272414, Los Angeles

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT06953960

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

City of Hope National Medical Center, Duarte
City of Hope - Lennar Foundation Cancer Center, Irvine

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Sult 2026 · NCT07555938

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Chao Family Comprehensive Cancer Center UCI, Orange

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT06980480

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

City of Hope, Duarte
Stanford University, Palo Alto
UCSF, San Francisco

A’ fastadhÌre 1

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Lùna 2026 · NCT07075185

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

UC Irvine Health, Orange

A’ fastadhÌre 1

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Lùna 2026 · NCT06375044

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Research Site, Duarte

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 27 Lùna 2026 · NCT07681596

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

GSK Investigational Site, Los Alamitos
GSK Investigational Site, Torrance
GSK Investigational Site, Whittier

A’ fastadhÌre 2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT07227311

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Beverly Hills Cancer Center, Beverly Hills
Clovis Community Medical Center, Clovis
Community Cancer Institute, Clovis
agus 9 a bharrachd

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Lùna 2026 · NCT06152575

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
Mercy Cancer Center - Carmichael, Carmichael
Mercy San Juan Medical Center, Carmichael
agus 9 a bharrachd

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 19 Lùna 2026 · NCT04566328

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

Research Site, Duarte
Research Site, Irvine

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 19 Lùna 2026 · NCT06106945

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

GSK Investigational Site, Los Angeles

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 19 Lùna 2026 · NCT05714839

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic, San Francisco

A’ fastadhÌre 1

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Lùna 2026 · NCT05651932

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

City of Hope, Duarte

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Lùna 2026 · NCT06292780

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Research Site, La Jolla
Research Site, Los Angeles
Research Site, San Francisco

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Lùna 2026 · NCT05850234

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Research Site, Orange
Research Site, Santa Monica

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Lùna 2026 · NCT07764978

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

UC Davis Comprehensive Cancer Center, Sacramento
UCLA Health, Jonsson Comprehensive Cancer Center, Santa Monica

A’ fastadhÌre 1

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 12 Lùna 2026 · NCT07280013

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Cedars-Sinai Medical Center, Los Angeles

A’ fastadhÌre 1

Aoisean 18 gu 85 · Gach gnè · Air ùrachadh 10 Lùna 2026 · NCT05887167

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.